SEC Filing Document

Company: DUKE Robotics Corp.
Ticker: DUKR
CIK: 1638911
Filing Type: DRS
Document Type: DRS
Date Filed: 2025-12-22
Accession Number: 0001213900-25-124553
Exchange: OTC
SIC Code: 3721
SIC Description: Aircraft
URL: https://www.sec.gov/Archives/edgar/data/1638911/000121390025124553/filename1.htm

Chunk 0 of 51
Word Count: 1444
Character Count: 9097

Document Content:

As confidentially
submitted to the Securities and Exchange Commission on December 22, 2025. This draft registration statement has not been filed publicly
with the Securities and Exchange Commission and all information herein remains strictly confidential.

Registration

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-1

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

DUKE Robotics Corp.

(Exact name of registrant as specified in its charter)

Nevada 3721 47-3052410

(State or other jurisdiction of
incorporation or organization) (Primary Standard Industrial
Classification Code Number) (I.R.S. Employer
Identification Number)

10 HaRimon Street, Mevo Carmel Science
and Industrial Park,

Israel, 2069203

(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)

Yossef Balucka

Chief Executive Officer

10 HaRimon Street, Mevo Carmel Science
and Industrial Park,

Israel, 2069203

(Name, address, including zip code, and telephone
number, including area code, of agent for service)

With copies to:

Alexander R. McClean, Esq.
C. Christopher Murillo, Esq.
Harter Secrest & Emery LLP
1600 Bausch & Lomb Place
Rochester, New York 14604
Tel: (585) 232-6500
Fax: (585) 232-2152	Oded Har-Even, Esq.
Ron Ben-Bassat, Esq.
Sullivan and Worcester LLP
1251 Avenue of the Americas, 19 th  Floor
New York, NY 10020
Tel: (212) 660-3000

Approximate date of commencement of proposed sale
to the public: As soon as practicable after this Registration Statement is declared effective.

If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:

If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large
accelerated filer	☐	Accelerated
filer	☐

Non-accelerated
filer	☒	Smaller
reporting company	☒

Emerging
growth company	☐

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting
pursuant to said Section 8(a), may determine.

The information in this prospectus
is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these securities and the Company is not soliciting an offer to buy these
securities in any jurisdiction where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS	SUBJECT TO COMPLETION, DATED [_], 2025

[    ] Units

Each Unit Consisting of

One Share of Common Stock and

One Warrant to Purchase One Share of Common Stock

This is a firm commitment underwritten public offering of [   ]
of units (the “Units”), based on a public offering price of $[   ] per Unit, of DUKE Robotics Corp., a Nevada
corporation (the “Company”, “we”, “us” or “our”). We anticipate a public offering price
between $[   ] and $[   ] per Unit. Each Unit consists of one share of common stock, $0.0001 par value per
share (“common stock”), and one warrant to purchase one share of common stock at an exercise price of $[   ]
per share ([   ]% of the price of each Unit sold in this offering based on a public offering price of $[   ] per Unit). The
Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The shares of common stock and the
warrants comprising the Units must be purchased together in this offering as Units and are immediately separable and will be issued separately
in this offering. Each warrant offered hereby is immediately exercisable on the date of issuance and will expire five years from the date
of issuance.

Our common stock is presently traded on the over-the-counter
market and quoted on the OTCQB tier operated by the OTC Markets Group Inc. (the “OTCQB”) under the symbol “DUKR.”
On December [_], 2025, the last reported sale price of our common stock was $[_] per share. We intend to apply to list our common stock
and warrants on the Nasdaq Capital Market under the symbol “DUKR” and “DUKRW” respectively. No assurance can be
given that our application will be approved or that the trading prices of our common stock on the OTCQB will be indicative of the prices
of our common stock if our common stock were traded on the Nasdaq Capital Market. If our listing application is not approved by the Nasdaq
Capital Market, we will not be able to consummate the offering and will terminate this offering.

There is no established public trading market
for the Units or the warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Units or the warrants
on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Units
and the warrants will be limited.

The offering price of the Units will be determined
between the underwriters and us at the time of pricing, considering our historical performance and capital structure, prevailing market
conditions, and overall assessment of our business, and may be at a discount to the current market price.

We expect to effect a [   ]-for-[   ] reverse stock
split of our outstanding common stock following the effective time of the registration statement to which this prospectus forms a part
but prior to the closing of this offering.

Investing in our securities involves a high
degree of risk. See “Risk Factors” beginning on page 9 of this prospectus. You should carefully consider these risk factors,
as well as the information contained in this prospectus, before you invest.

Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus.
Any representation to the contrary is a criminal offense.

Per Unit Total

Public offering price $ $

Underwriting discount and commissions (1) $ $

Proceeds to us before offering expenses (2) $ $

(1)	We have also agreed to issue warrants to purchase shares of our common stock to the representative of the underwriters in this offering and to reimburse the representative of the underwriters for certain expenses. See “Underwriting” for additional information regarding total underwriter compensation, including information on underwriting discounts and offering expenses.

(2)	The amount of offering proceeds to us presented in this table does not give effect to any exercise of the: (i) over-allotment option (if any) we have granted to the representative of the underwriters as described below, (ii) the warrants included in the Units offered hereby, and (iii) warrants being issued to the representative of the underwriters in this offering.

This Offering is being conducted on a firm commitment
basis. The underwriters are obligated to take and pay for all the Units offered by this prospectus if any such Units are taken.

We have granted a 45-day option to the representative
of the underwriters, exercisable one or more times in whole or in part, to purchase up to an additional [   ] shares of common stock and/or
[   ] additional warrants at a price from us in any combination thereof at the public offering price per share of common stock and $0.0001
per warrant, respectively, less the underwriting discounts payable by us, solely to cover over-allotments, if any.